Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of RJMty19 in Treatment of Subjects With Refractory Systemic Lupus Erythematosus

NCT06340490 is registered in ClinicalTrials.gov with Guangdong Ruishun Biotech Co., Ltd as lead sponsor.

NCT NCT06340490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of RJMty19 in Treatment of Subjects With Refractory Systemic Lupus Erythematosus
Lead sponsor
Guangdong Ruishun Biotech Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 15, 2024
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus